Pfizer had a hand in creating one of the biggest vaccines protecting people against COVID-19. Now it’s working to creat one that protects against COVID and the flu at the same time.
Phase one of the study was announced with BioNTech and an mRNA-based combo of the vaccine.
The announcement was made by Pfizer on their Twitter account on Nov. 3. The first participant has been chosen to receive a dose in a phase one trial, according to My Twin Tiers.
The team will then analyze the safety, tolerability, and immunogenicity of a person who gets one vaccine that protects against both diseases.
This study is to evaluate the safety and figure out the best dosage for the combined vaccine against COVID and the flu.
The study is happening in the U.S. and will enroll 180 healthy volunteers between the ages of 18 and 64.
Each participant will have a follow up after 6 months.
There are three categories of information surrounding this vaccine.
First is the fact that the combination approach’s goal is to protect people against two very severe respiratory viruses.
Next, the vaccines are a combined dose of both COVID and the flu vaccines, but more specifically the vaccine against the Omicron variants. That includes BA.4 and BA.5.
Finally, the third most important part is that first person of 180 participants was given a dose this week, and the follow up of each one will determine the outcomes of the first two categories.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].